Cipla Medpro has entered into an exclusive agreement with Serum Institute of India (SII) in South Africa to enable affordable and accessible vaccines for South Africans and a reliable supply stream to the South African government. auremar - ... Biz Community, 3 weeks ago
Cipla announces Africa expansion strategy - Pharmaceutical & Cosmetic Review, 3 weeks ago
Cipla aims to make biosimilars affordable with new South African plant - Business Standard India, 1 month ago
1 images for "cipla medpro"
Cipla Medpro, Cipla Ltd's biotech subsidiary in South Africa, will invest just over R1.3 billion into the country's first state-of-the-art biotech manufacturing facility, for the production of biosimilars. Steven Lehrer, Director of Cipla BioTec ...Pharma Business International, 1 month ago Cipla to build SA biosimilar factory Crown.co.za, 1 month ago Cipla to make low-cost biosimilars in South Africa FiercePharma, 1 month ago Cipla to build biosimilars plant in South Africa to serve global markets BioPharma-Reporter.com, 1 month ago
More from: PharmaBiz, PharmaBiz...and 15 other sources
Cipla successfully completes its move to new warehouse facility with Cquential WMS - sophisticated Cloud Warehouse Management solution. Towards the end of last year, Cipla one of South Africa's leading pharmaceutical manufacturers - commenced a ...Supply Chain Update, 1 month ago Cipla Medpro chooses Cquential Warehouse Management IT-Online, 1 month ago
inlsa Cipla Medpro. Photo: Supplied. Johannesburg - Cipla's SA biotech subsidiary will invest R1.3 billion into a new factory in KwaZulu-Natal to produce biosimilars. The investment was announced in a statement issued on Friday and notes that ...Sunday Tribune, 1 month ago CIPLA : to set up Rs.1.3-bn biotech plant in SA 4 Traders, 1 month ago
Cipla has appointed Umang Vohra as the managing director and global chief executive officer effective from 1 September Mumbai: Subhanu Saxena, chief executive officer (CEO) at Mumbai-based drug maker Cipla Ltd, will step down from his position on 31 ...Livemint.com, 1 week ago
Mr Chandru Chawla, head of Cipla New Ventures Singapore: Although currently small and focused on few diseases, the biosimilars opportunity is all set to grow, thanks to the unprecedented patent cliff and rising healthcare costs. Biosimilars are ...Bio Spectrum Asia, 2 weeks ago
Cipla has announced that it is currently developing an innovative inhaler, which will bring important benefits for South African patients and physicians, as the inhaler holds three key benefits for the treatment of Obstructive Airway Diseases (OAD).Biz Community, 3 weeks ago
SENSEX 27570.65 443.75 1.64% NIFTY 8448.50 125.30 1.51% Industries: Automobile, Banks & Finance, Engineering, Medical/Healthcare, Metal and Mining, Metal and Mining, Telecom Company Elgi Equipments Ltd , TVS Motor Company Ltd ...Finalaya.com, 1 month ago
The sport nutrition industry in South Africa is unregulated, unlike medicines, which are controlled by the Medicines Control Council. This leads to products being sold that may contain substance banned by WADA (World Anti-Doping Agency) and ...Biz Community, 3 weeks ago
With 55 doping violations between April 2011 and June 2012 in South Africa, the trend is increasing according to recent statistics released by the SA Institute for Drug Free Sport. However, while some athletes use drugs to seek a competitive ...Biz Community, 3 weeks ago
on your WebpageAdd Widget >Get your members hooked!